89 related articles for article (PubMed ID: 7881454)
1. Analysis of multiple-dose bioequivalence studies.
Chinchilli VM; Esinhart JD; Barr WH
J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
[TBL] [Abstract][Full Text] [Related]
2. The assessment of individual and population bioequivalence.
Chinchilli VM
J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
[TBL] [Abstract][Full Text] [Related]
3. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
[TBL] [Abstract][Full Text] [Related]
4. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
Mahmood I; Mahayni H
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
[TBL] [Abstract][Full Text] [Related]
5. The analysis of bioequivalence with respect to TMAX under a 2 x 2 crossover design.
Have TR; Ten Chinchilli VM
J Biopharm Stat; 1995 Jul; 5(2):185-99. PubMed ID: 7581427
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence review for drug interchangeability.
Chow SC; Shao J
J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers.
Silva Mde F; Schramm SG; Kano EK; Mori Koono EE; Porta V; dos Reis Serra CH
Clin Ther; 2010 Apr; 32(4):758-65. PubMed ID: 20435245
[TBL] [Abstract][Full Text] [Related]
9. The multivariate assessment of bioequivalence.
Chinchilli VM; Elswick RK
J Biopharm Stat; 1997 Mar; 7(1):113-23. PubMed ID: 9056592
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
[TBL] [Abstract][Full Text] [Related]
11. A three-step procedure for assessing bioequivalence in the general mixed model framework.
Vuorinen J; Turunen J
Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
[TBL] [Abstract][Full Text] [Related]
12. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.
Endrenyi L; Fritsch S; Yan W
Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):394-9. PubMed ID: 1748540
[TBL] [Abstract][Full Text] [Related]
13. Optimal sampling times in bioequivalence tests.
Kong FH; Gonin R
J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
[TBL] [Abstract][Full Text] [Related]
14. On assessment of bioequivalence under a higher-order crossover design.
Chow SC; Liu JP
J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
Cho HY; Moon JD; Lee YB
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
[TBL] [Abstract][Full Text] [Related]
18. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
Chen YI; Huang CS
Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence evaluation of 2 different oral formulations of ciprofloxacin in healthy volunteers.
Galicia I; Frias-Iniesta J; Carcas AJ; Soto A; Gomez E; Miranda E; Fernandez A; Montuenga C
Int J Clin Pharmacol Ther; 1998 May; 36(5):282-5. PubMed ID: 9629993
[TBL] [Abstract][Full Text] [Related]
20. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
Lee JY; Kim BC; Park SG
J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
